FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223443163> ?p ?o ?g. }

• W4223443163 endingPage "1707" @default.
• W4223443163 startingPage "1695" @default.
• W4223443163 abstract "Current standard of care for metastatic castration-sensitive prostate cancer supplements androgen deprivation therapy with either docetaxel, second-generation hormonal therapy, or radiotherapy. We aimed to evaluate the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care.We conducted an open-label, randomised, phase 3 study with a 2 × 2 factorial design (PEACE-1) at 77 hospitals across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland. Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma, and an Eastern Cooperative Oncology Group performance status of 0-1 (or 2 due to bone pain). Participants were randomly assigned (1:1:1:1) to standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m2 once every 3 weeks), standard of care plus radiotherapy, standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily), or standard of care plus radiotherapy plus abiraterone. Neither the investigators nor the patients were masked to treatment allocation. The coprimary endpoints were radiographic progression-free survival and overall survival. Abiraterone efficacy was first assessed in the overall population and then in the population who received androgen deprivation therapy with docetaxel as standard of care (population of interest). This study is ongoing and is registered with ClinicalTrials.gov, NCT01957436.Between Nov 27, 2013, and Dec 20, 2018, 1173 patients were enrolled (one patient subsequently withdrew consent for analysis of his data) and assigned to receive standard of care (n=296), standard of care plus radiotherapy (n=293), standard of care plus abiraterone (n=292), or standard of care plus radiotherapy plus abiraterone (n=291). Median follow-up was 3·5 years (IQR 2·8-4·6) for radiographic progression-free survival and 4·4 years (3·5-5·4) for overall survival. Adjusted Cox regression modelling revealed no interaction between abiraterone and radiotherapy, enabling the pooled analysis of abiraterone efficacy. In the overall population, patients assigned to receive abiraterone (n=583) had longer radiographic progression-free survival (hazard ratio [HR] 0·54, 99·9% CI 0·41-0·71; p<0·0001) and overall survival (0·82, 95·1% CI 0·69-0·98; p=0·030) than patients who did not receive abiraterone (n=589). In the androgen deprivation therapy with docetaxel population (n=355 in both with abiraterone and without abiraterone groups), the HRs were consistent (radiographic progression-free survival 0·50, 99·9% CI 0·34-0·71; p<0·0001; overall survival 0·75, 95·1% CI 0·59-0·95; p=0·017). In the androgen deprivation therapy with docetaxel population, grade 3 or worse adverse events occurred in 217 (63%) of 347 patients who received abiraterone and 181 (52%) of 350 who did not; hypertension had the largest difference in occurrence (76 [22%] patients and 45 [13%], respectively). Addition of abiraterone to androgen deprivation therapy plus docetaxel did not increase the rates of neutropenia, febrile neutropenia, fatigue, or neuropathy compared with androgen deprivation therapy plus docetaxel alone.Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients.Janssen-Cilag, Ipsen, Sanofi, and the French Government." @default.
• W4223443163 created "2022-04-14" @default.
• W4223443163 creator A5001456598 @default.
• W4223443163 creator A5001484228 @default.
• W4223443163 creator A5001628805 @default.
• W4223443163 creator A5001994148 @default.
• W4223443163 creator A5003798935 @default.
• W4223443163 creator A5006249276 @default.
• W4223443163 creator A5007779528 @default.
• W4223443163 creator A5011506675 @default.
• W4223443163 creator A5012051564 @default.
• W4223443163 creator A5012288965 @default.
• W4223443163 creator A5014074160 @default.
• W4223443163 creator A5015024874 @default.
• W4223443163 creator A5020692060 @default.
• W4223443163 creator A5021549650 @default.
• W4223443163 creator A5023596460 @default.
• W4223443163 creator A5027125202 @default.
• W4223443163 creator A5027911519 @default.
• W4223443163 creator A5031054777 @default.
• W4223443163 creator A5032040129 @default.
• W4223443163 creator A5032046202 @default.
• W4223443163 creator A5040171322 @default.
• W4223443163 creator A5047946219 @default.
• W4223443163 creator A5049444901 @default.
• W4223443163 creator A5050184458 @default.
• W4223443163 creator A5057183350 @default.
• W4223443163 creator A5063584845 @default.
• W4223443163 creator A5064864169 @default.
• W4223443163 creator A5067036952 @default.
• W4223443163 creator A5068223483 @default.
• W4223443163 creator A5073583906 @default.
• W4223443163 creator A5077881511 @default.
• W4223443163 creator A5081519723 @default.
• W4223443163 creator A5089019258 @default.
• W4223443163 date "2022-04-01" @default.
• W4223443163 modified "2023-10-18" @default.
• W4223443163 title "Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design" @default.
• W4223443163 cites W2010840107 @default.
• W4223443163 cites W2090233519 @default.
• W4223443163 cites W2142466432 @default.
• W4223443163 cites W2150865892 @default.
• W4223443163 cites W2167331614 @default.
• W4223443163 cites W2168108459 @default.
• W4223443163 cites W2214621962 @default.
• W4223443163 cites W2264105361 @default.
• W4223443163 cites W2472429093 @default.
• W4223443163 cites W2533072646 @default.
• W4223443163 cites W2620746860 @default.
• W4223443163 cites W2620798309 @default.
• W4223443163 cites W2743936472 @default.
• W4223443163 cites W2787804990 @default.
• W4223443163 cites W2788841415 @default.
• W4223443163 cites W2795813205 @default.
• W4223443163 cites W2802053856 @default.
• W4223443163 cites W2890444045 @default.
• W4223443163 cites W2897236707 @default.
• W4223443163 cites W2938589827 @default.
• W4223443163 cites W2947893479 @default.
• W4223443163 cites W2975895768 @default.
• W4223443163 cites W3006901903 @default.
• W4223443163 cites W3010077430 @default.
• W4223443163 cites W3092344805 @default.
• W4223443163 cites W3127066344 @default.
• W4223443163 cites W3158318954 @default.
• W4223443163 cites W3191534679 @default.
• W4223443163 cites W3202107108 @default.
• W4223443163 cites W3216743998 @default.
• W4223443163 doi "https://doi.org/10.1016/s0140-6736(22)00367-1" @default.
• W4223443163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35405085" @default.
• W4223443163 hasPublicationYear "2022" @default.
• W4223443163 type Work @default.
• W4223443163 citedByCount "191" @default.
• W4223443163 countsByYear W42234431632022 @default.
• W4223443163 countsByYear W42234431632023 @default.
• W4223443163 crossrefType "journal-article" @default.
• W4223443163 hasAuthorship W4223443163A5001456598 @default.
• W4223443163 hasAuthorship W4223443163A5001484228 @default.
• W4223443163 hasAuthorship W4223443163A5001628805 @default.
• W4223443163 hasAuthorship W4223443163A5001994148 @default.
• W4223443163 hasAuthorship W4223443163A5003798935 @default.
• W4223443163 hasAuthorship W4223443163A5006249276 @default.
• W4223443163 hasAuthorship W4223443163A5007779528 @default.
• W4223443163 hasAuthorship W4223443163A5011506675 @default.
• W4223443163 hasAuthorship W4223443163A5012051564 @default.
• W4223443163 hasAuthorship W4223443163A5012288965 @default.
• W4223443163 hasAuthorship W4223443163A5014074160 @default.
• W4223443163 hasAuthorship W4223443163A5015024874 @default.
• W4223443163 hasAuthorship W4223443163A5020692060 @default.
• W4223443163 hasAuthorship W4223443163A5021549650 @default.
• W4223443163 hasAuthorship W4223443163A5023596460 @default.
• W4223443163 hasAuthorship W4223443163A5027125202 @default.
• W4223443163 hasAuthorship W4223443163A5027911519 @default.
• W4223443163 hasAuthorship W4223443163A5031054777 @default.
• W4223443163 hasAuthorship W4223443163A5032040129 @default.
• W4223443163 hasAuthorship W4223443163A5032046202 @default.
• W4223443163 hasAuthorship W4223443163A5040171322 @default.
• W4223443163 hasAuthorship W4223443163A5047946219 @default.

• next